top of page
Patient on Scale

Revitalize Your Beauty With Mounjaro (Tirzepatide) Injection

Renew ND Medspa offers the latest Mounjaro (Tirzepatide) injections to help you achieve your beauty and wellness goals. Our experienced team provides personalized treatment plans to enhance your natural beauty and boost your confidence.

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

What Is It About?

Tirzepatide, the peptide responsible for the benefits seen with Mounjaro, is an injectable prescription that improves blood sugar (glucose) in adults with type 2 diabetes. Studies now show that Mounjaro shows promising weight loss effects, including managing weight, reducing hunger, regulating blood sugar, improving metabolic health goals, and more. As a dual GIP and GLP-1 receptor, Mounjaro is the first drug of its kind. As a result, many people consider it a game changer for several reasons, including its ability to improve blood sugar levels and enhance weight loss.

 

Benefits of Mounjaro (Tirzepatide)

  • Helps improve health conditions of patients with type 2 diabetes

  • Given as a once-weekly injection

  • Reduces hemoglobin A1C levels

  • Achieves optimal metabolic health goals

 

 How Mounjaro Enhances Weight Loss

  • Mounjaro works the same as other drugs in the Glucagon-like peptide-1 (GLP-1) family, like forms of Semaglutide. However, it contains an extra molecule that gives it an edge. The dual-action design mimics the action of not one but two incretin hormones involved in blood sugar control: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). The unique dual action makes Mounjaro the first-in-class medication that acts on both receptors.

  • In a press release published by Eli Lilly, “GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, resulting in weight reductions. When combined with GLP-1 receptor agonist, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose, and lipids.”

 

Mounjaro in Clinical Studies

  • Several clinical studies and trials back Mounjaro. One study shows that when Mounjaro is taken with or without other diabetes medications, the percentage of people taking it reaches an A1C of less than 7%, ranging from 75% (5mg) to 90% (10mg). People with an average starting A1C of 7.9% to 8.6% across the 5mg, 10mg, and 15mg doses.

  • The 40-week study was completed to show if Mounjaro medication plus basal insulin worked better than basal insulin alone. Of the 90% of people taking Mounjaro plus basal insulin, each achieves an A1C of under 7%.

  • Ready to start? Call/text 425-551-7573 to begin your weight loss journey.

Contact

Your dream face and body destination. Let's connect!

425-551-7573

bottom of page